Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. by Stouthard, J. M. et al.
Britsh Journal of Cancer (1996) 73, 789-793
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 $0
Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II
trial
JML Stouthard', H Goey2, EGE de Vries3, PH de Mulder4, A Groenewegen5, L Pronk2, G Stoter2,
HP Sauerwein6, PJM Bakker1 and CHN Veenhof
'Department ofMedical Oncology, Academic Medical Center, University ofAmsterdam, PO Box 22700, 1100 DE Amsterdam; 2Dr
Daniel Den Hoed Kliniek, Groene Hillendijk 301, 3075 EA Rotterdam; 3University Hospital Groningen, Oostersingel 59, 9713 EZ
Groningen; 'University Hospital St. Radboud, G. Grooteplein 8, 6525 GA Nijmegen; 5Sandoz Medical Research Department, PO
Box 91, 5400 AB Uden; 6Metabolic Research Group, Department ofInternal Medicine, Academic Medical Center, University of
Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands.
Summary A phase II trial investigating the anti-tumour effects of recombinant human interleukin 6 (rhIL-6)
in patients with metastatic renal cell cancer was carried out. RhIL-6 (150,g) was administered as a daily
subcutaneous injection for 42 consecutive days on an outpatient basis. Forty-nine patients were studied, 12
with and 37 without previous immunotherapy. Forty patients were evaluable for response. A partial remission
was noted in two patients, stable disease in 17 and progressive disease in 21. Toxicity was moderate and
reversible and consisted mainly of fever, flu-like symptoms, nausea, weight loss and hepatotoxicity. Anaemia,
leucocytosis and thrombocytosis and induction of acute phase protein synthesis were noted in most patients. In
15% of the patients anti-IL-6 antibodies developed, and were neutralising in only one patient. Baseline plasma
IL-6 concentrations did not correlate with tumour behaviour before or after rhIL-6 treatment. In conclusion,
rhIL-6 can be safely administered on an outpatient basis for a prolonged period of time and has moderate,
reversible toxicity. Its administration induces IL-6-antibody production in only a minority of patients. Anti-
tumour effects of rhIL-6 in metastatic renal cancer are limited.
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Metastatic renal cell carcinoma has a poor prognosis for
most patients, with a median survival of less than 1 year
(Marston et al., 1989). Efforts to improve this survival by
chemotherapeutic agents have been largely unsuccessful
(Yagoda et al., 1993). Recently, immunotherapy has received
much attention (Wirth, 1993). Although a moderate
effectiveness of both IL-2 and interferon-a has been
observed, long-term disease-free survival after treatment
with cytokines has not been documented in a randomised
fashion (Wirth, 1993). Therefore, the need for new effective
and safe therapies remains.
Interleukin 6 (IL-6) is a multifunctional cytokine (Le and
Vilcek, 1989) that has stimulatory effects on thrombocytopoi-
esis (Ishibashi and Asano, 1992), B- and T-cell differentiation
(Kishimoto and Hirano, 1988; Houssiau and Van Snick,
1992) and the hepatic acute phase response (Gauldie et al.,
1992), as well as a mediatory role in the metabolic and
endocrinological response to inflammation (Stouthard et al.,
1994, 1995). Furthermore, experimental and preclinical data
indicate that IL-6 may have direct and indirect anti-tumour
activity in solid tumours (Revel, 1992; Chen et al., 1988;
Mule et al., 1990, 1992).
Here, we describe our results of a multicentre phase II trial
of recombinant human (rh)IL-6 in patients with metastatic
renal cell cancer. This study was initiated after the
observation of a complete remission of pulmonary metas-
tases in a patient with renal cell carcinoma after a 6 week
course of daily subcutaneous recombinant human IL-6 (rhIL-
6) injections as an experimental drug for thrombocytopenia
(A Gianella-Borradori, personal communication). Using the
same treatment schedule, we investigated anti-tumour effects,
toxicity, haematological and biochemical changes and the
induction of anti-IL-6 antibodies in patients with metastatic




Eligible for this study were all patients with a histologically
verified diagnosis of metastatic renal cell cancer, with
bidimensionally measurable tumour lesions and who were
between 18 and 75 years of age. Their WHO performance
status had to be 0 or 1, and their life expectancy at least 3
months. Patients were required to have a haemoglobin level
c5 mmol I`, a white blood count >3.0x 10l-' and
thrombocyte count > 100 x 109
1I, normal liver function as
assessed by bilirubin <25 umol l-1 (in case of hepatic
metastases <50 ymol l-') and normal renal function
(creatinine <175 imol 1`). Excluded were patients with a
nephrectomy, chemotherapy or therapy with any investiga-
tional drug within 4 weeks of study entry, patients with brain
metastases, with known HIV, viral hepatic or Epstein-Barr
virus (EBV) infection, with severe allergic disease, uncon-
trolled psoriasis, severe rheumatoid arthritis, glomerulone-
phritis or any other severe autoimmune disease and those on
immunosuppressive therapy (corticosteroids) and pregnant
women. The study was approved by the Medical Ethical
Committees of all participating centres. All patients gave
written informed consent.
Study design
This was an open, non-randomised multicentre phase II study
in which four centres participated. All centres included at
least seven patients. Before the start of the study a complete
medical history, including past therapy for the renal cancer
with record of all surgical and radiotherapeutic procedures
and therapeutic agents used, was obtained. Patients were
stratified by previous use of immunotherapy (e.g. interleukin
2, interferons or any other immunomodulating therapy)
(group I) or not (group II). The treatment in both groups
was identical and consisted of daily subcutaneous (s.c.)
injection of 150 Hg of Escherichia coli derived rhIL-6 (108
units mg-' protein) for 42 consecutive days. Before s.c.
injection, the rhIL-6 vial was reconstituted in 1 ml of sterile
water. After instructions on injection technique by an
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oncology nurse, rhIL-6 was injected in the upper leg on an
inpatient basis on days 1-3 and subsequently rhIL-6 was
self-administered upon discharge home. Acetaminophen, with
a maximum of 3 g per day, was prescribed for fever or flu-
like symptoms. RhIL-6 (SDZ ILS 969), provided by Sandoz
Pharma. (Basle, Switzerland), was >99% pure (as assessed
by SDS-PAGE) and contained <0.4 endotoxin units mg-
(Limulus amoebocyte lysis assay).
Vital signs and reports of symptoms or adverse events
were recorded and scored according to the National Cancer
Institute of Canada Clinical Trials Group Expanded
Common Toxicity Criteria (NCIC criteria) (Vantongelen,
1991) on day 1 and weekly thereafter. On days 1, 22 and 42
physical examination was performed and performance status
recorded. Tumour measurements by radiological or clinial
evaluation were performed just before the start of the study,
at the end of the treatment, after 4 weeks follow-up and,
when possible, every 2 months thereafter.
Laboratory investigations
Complete blood counts, prothrombin time, biochemistry
[bilirubin, creatinine, sodium, potassium, alanine-amino
transferase, aspartate-amino transferase, alkaline phospha-
tase (AP), gamma-glutamyltransferase (y-GT), acute phase
reactants (erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), fibrinogen) and urinalysis] were obtained
weekly, beginning at day 1. On day 1, before the first rHIL-6
administration, blood was obtained for the measurement of
baseline IL-6 concentrations (Quantikine, R&D Systems,
Minneapolis, MN, USA; detection limit 0.003 ng ml'). On
days 1, 22 and 42 blood was sampled for qualitative and, if
positive, quantitative analysis of anti-rhIL-6 antibodies. For
the qualitative analysis of anti-IL-6 antibodies a 'screen
ELISA' was used. In short, microtitre plates, coated with
SDZ ILS 969 in coating buffer, were incubated with positive
and negative antibody controls and with heat-inactivated
patient serum in triplicate. After incubation alkaline
phosphatase-conjugated goat anti-human IgG + IgM +
IgA was added. After addition ofp-nitrophenyl phosphate in
diethanolamine optical density was read using an UVmax
microtitre plate reader at 405-650 nm. An optical density of
, 0.305 was found in 95% of normal individuals, and
considered the cut-off for being antibody-negative for SDZ
ILS 969. If a higher value was found, a quantitative analysis
of anti-IL-6 antibodies was performed, using ELISA.
Microtitre plates were coated as described above, either
with coating buffer alone or with coating buffer containing
SDZ ILS 969. Serum samples and controls were added in 3-
fold serial dilutions (starting at 1:100) and processed as
described. The specific optical density (OD) was defined as
the OD of the sample in the well that was coated with SDZ
ILS 969 minus the OD of the sample in the well that was
coated with coating buffer only. For a claim of immuno-
genecity, a patient had to have a treatment-specific OD value
of at least twice the pretreatment specific OD value. Values of
the quantitative analysis were expressed as positive at a given
titre.
Neutralising antibodies to rhIL-6 were detected using a
IL-6 growth-dependent cell line (B13.29), with neutralising
antiserum obtained from a goat as a positive control. A
serum sample was considered as positive for neutralising
antibodies if it inhibited the proliferative response to 5
units ml-' rhIL-6, and if the percentage inhibition was at
least twice the percentage inhibition of the pretreatment
serum sample at the equivalent dilution.
Response criteria
Only patients who completed the 6 week treatment period
were included in the evaluation. A complete response was
defined as the total disappearance of all detectable malignant
disease for at least 4 weeks. A partial response was defined as
a >50% reduction of (the sum of) the product(s) of the
longest diameter and the greatest perpendicular diameter of a
given lesion(s) (diameter product), and no appearance of new
lesions for at least 4 weeks. A minor response was defined as
a reduction of >25% but <50% by the same definitions.
Stable disease was noted when the (sum of the) diameter
product(s) decreased <50% or increased <25%. Progressive
disease was defined as an increase >25% of the diameter
product(s) of a measurable lesion, in the sum of the products
of individual lesions or in case of the appearance of new
lesions. Tumour status at entry was defined by the same
criteria using measurements obtained in the 3 months
preceding study entry, whenever available.
Statistics
To assess anti-tumour activity, an Optimal Two-Stage Early
Rejection Design (Simon, 1987) was used: assuming a 20%
response rate would indicate treatment effectiveness, 12
patients were to be recruited in each group in the first
stage. If one or more responses were observed, the trial
would enter a second stage and a total (per group) of 37
patients would be recruited. All laboratory data are presented
as mean+ s.e.m. Changes in any laboratory parameter during
the rhIL-6 treatment were evaluated using analysis of
variance, and, where appropriate, by Newman-Keul's test
for multiple comparisons. Differences between groups were
evaluated by Mann-Whitney's t-test for unmatched samples.




The demographic and disease characteristics of the patients
are given in Table I. A total of 49 patients was included; 12
patients with, and 37 patients without previous immunother-
apy. There were no significant differences between the two
groups. Of the previously treated patients, five received IL-2,
four IL-2 + a-interferon (a-IFN) + lymphokine-activated
killer cells, and three received oc-IFN. The median interval
until start of the IL-6 treatment was 8 (range 3-32) months.
Two patients had a partial remission, whereas none of the
others responded.
Tumour responses
The responses to rhIL-6 treatment are given in Table II. In
the group that had had previous immunotherapy, 10 out of
12 patients were evaluable for response. There were no
minor, partial or complete responses observed. Stable disease
was noted in five patients. Of the five patients who had stable
Table I Patient characterisitcs
P-value
I II Ivs II
Number of patients 12 37
Age (years) 59±2 61+2 NS
Sex (male/female) 8/4 29/8 NS
Time from diagnosis to treatment 27±9 29+8 NS
(months)
Tumour statusa (stable/progressive) 5/4 11/15 NS
Performance (0/1) 5/7 21/16 NS
Metastatic sites
Lung 8 25 NS
Bone 1 7 NS
Other 7 15 NS
Nephrectomy 6 24 NS
Previous radiotherapy 5 10 NS
Previous chemotherapy 2 8 NS
a Data not available for all patients. b Total number may exceed
number ofpatients owing tomultiplemetastatic sites in somepatients.
NS, not significant.Interleukin 6 in renal cell cancer
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Table II Tumour response after 6 weeks of rhIL-6 treatment in
patients with (I) and without (II) prior immunotherapy
I II
Complete remission - -
Partial remission - 2
Stable disease 5 12
Progressive disease 5 16
disease at entry, three remained stable. Two of the four
patients with progressive disease at entry had stable disease at
the end of the treatment.
In the group without prior immunotherapy, two partial
responses were noted. One partial response occurred in a 66
year-old male with pulmonary and liver metastases that
progressed on chemotherapy with fluorodeoxyuridine, admi-
nistered until 2 months before rhIL-6 treatment. A radical
nephrectomy had been performed 36 months before. The
patient noticed a considerable improvement in well-being
while on rhIL-6 treatment. At the end of the 6 week rhIL-6
treatment course an approximately 60% tumour reduction
was noted, with a further reduction during the next 10 weeks
(total tumour reduction 80%). A second 6 week rhIL-6
treatment, initiated 4 months later because of recurrent
disease, unfortunately failed to reinduce a remission. The
other partial response was observed in a 65-year-old male
who underwent a radical nephrectomy 36 months before, and
who had para-aortic lymph node metastases that were
progressive at study entry. After 6 weeks of rhIL-6 treatment
stable disease was noted. Three months later, without any
subsequent treatment, a partial remission was found on the
basis of a 55% reduction in diameter product, that lasted 2
months. Of the other 35 patients in this group, 28 were
evaluable for tumour response; 12 had stable disease, 16 had
progressive disease. There were no minor responses. Seven of
the 11 patients who had stable disease at entry, remained
stable. Of the 15 patients who had progressive disease at the
start of the rhIL-6 treatment, one had a partial response (see
above) and four were stable throughout the treatment period.
Toxicity
Side-effects are summarised in Table III. All patients were
evaluable for toxicity, and since there were no differences in
side-effects between patients with or without previous
immunotherapy, the data of group I and II were pooled.
The main side-effects were fever (89% of the patients),
favourably responding to acetaminophen in most patients;
flu-like symptoms such as fatigue (22%), headache (14%) and
myalgia or arthralgia (12%); nausea (37%); weight loss
(37%); and hepatotoxicity, as indicated by increases in AF
Table HI Toxicity, according to NCIC criteria, during rhIL-6
treatment. No grade 4 toxicity was observed
NCIC grade 1 2 3
Fever 21 23
Anaemia 19 8 1
tAF 20 10 1
ty-GT15 10 5
Nausea 14 2 2
Vomiting 2 2 1
Weight loss 17 1
Fatigue 4 5 2
Headache 7 - -
Myalgia/arthralgia 5 1
Dizziness - - 1
Mental depression - - 1
Stomatitis 3
Diarrhoea 2 - -
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(63%) and y-GT (61%). Two patients developed hypercal-
caemia during rhIL-6 treatment. One patient had rapid
progression of this disease. The other patient had stable
disease. After institution of biphosphonate therapy his
plasma calcium levels normalised. Finally, all patients had
local erythema at the injection site, which subsided within
48 h. All toxicity reversed within 4 weeks after discontinua-
tion of the rhIL-6 treatment. Nine patients had to
discontinue rhIL-6 treatment prematurely, i.e. after a mean
of 31 weeks: two patients in group I and seven in group II.
The reasons for discontinuing rhIL-6 treatment were fatigue,
leading to semi permanent bedrest, in two patients,
accompanied by severe mental depression in one; deteriora-
tion of their general condition due to tumour progression in
three patients; gross haematuria due to haemorrhage from
the primary tumour in the kidney, with subsequent urosepsis,
in one patient; hemiparesis due to tumour progression, for
which radiation therapy had to be instituted, in one patient;
fatal cerebral haemorrhage, without evidence of central
nervous system metastases on CT scanning, but with a
history of hypertension, in one patient; lack of ability to
comply with the protocol in one patient.
Haematology and acute phase response
Figures 1 and 2 show the time course of the haematological
effects of and the acute phase response to rhIL-6 treatment.
Anaemia was a frequently noted side-effect, necessitating
blood transfusions in 13 patients. Haemoglobin content
progressively declined during the rhIL-6 administration by a
mean of approximately 19% (from 8.5+0.2 to
6.5+0.1 mmol 1-1, baseline vs nadir P<0.001). At week 10,
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Figure 1 Changes in leucocyte (a) and thrombocyte (b) counts
(in 1091-1) (mean+s.e.m.) during and after rhIL-6 treatment.
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Figure 3 Baseline plasma IL-6 concentrations expressed as a
function of tumour status at study entry (a) or as a function of the
response to rhIL-6 treatment (b). Dotted line indicates detection
level of the IL-6 assay at 3pgml-1.
1 2 3 4 5 6
Weeks
Figure 2 Changes in fibrinogen (a) and




mean haemoglobin content in patients who did not receive a
blood transfusion was still lower than the baseline value.
Administration of rhIL-6 led to a significant increase in
leucocyte count (from 7.3+0.3 x 109 I` at baseline to
8.6+0.4x109 1- at week 3, P<0.001) (Figure 1), without
major changes in differential counts. A gradual increase of the
thrombocyte count, reaching a plateau after 3 weeks (from
298+15 to 456+17x1091-; baseline vs week 3, P<0.001)
was observed (Figure 1). At week 10 the thrombocyte count
was not different from baseline. RhIL-6 also induced an acute
phase response, as indicated by increases in CRP (from
28+5 mg 1-' at baseline to 149+7 mg l-' at week 2,
P<0.001) and fibrinogen (from 5.58+0.26 mg l-' to
8.76+0.36 mg l-l at week 2, P<0.001) (Figure 2). ESR
increased parallel to the increases in fibrinogen (from
47+5mmh- to 105+3mmh at week 2, P<0.001). At
week 10 CRP and fibrinogen concentration, but not ESR, had
returned to baseline values.
IL-6 concentrations and immunogenecity
Pretreatment samples for determination of IL-6 concentra-
tions and pre- and post-treatment samples for determination
of anti-IL-6 antibodies were received from 41 subjects. At
baseline the IL-6 concentrations were below the detection limit
in 17 subjects. Figure 3 shows the individual baseline IL-6
concentrations of the patients whose tumour status at entry
was known. Furthermore, baseline IL-6 concentrations in
relation to tumour response are given. From these data it can
be concluded that there was no statistically significant
difference in IL-6 concentrations between those who had
stable or progressive disease at entry, or between those who
did or did not respond to rhIL-6 treatment.
Anti-IL-6 antibodies were detected in five patients in group
I and in 1 patient in group II. On quantitative analysis, the
anti-IL-6 antibody titres varied from 1:100 to 1:300. Of these
patients, three had stable disease after rhIL-6 treatment, and
three had progressive disease. Neutralising antibodies were
only detectable in the one patient with anti-IL-6 antibodies in
group II. This patient had pulmonary metastases that were
stable at study entry, and his disease progressed during rhIL-6
treatment.
Discussion
This phase II trial investigated the anti-tumour effects of
interleukin 6 in metastatic renal cell cancer. Two partial
remissions were noted. Spontaneous tumour regression in
metastatic renal cell carcinoma, especially shortly after
surgical removal of the primary tumour, has been observed
in less than 1% of all patients (Marston et al., 1989).
However, since neither of these two patients underwent a
recent nephrectomy, the inhibition of tumour growth may
have been the consequence of the rhIL-6 administration. Anti-
tumour effects of IL-6 in experimental studies may be either
direct (Chen et al., 1988) or mediated by enhancing cytotoxic
T-lymphocytes (Mule et al., 1992; Porgador et al., 1992) or by
other as yet undefined routes. A non-direct anti-tumour effect
in our patients seems more likely, given the perpetuation of
tumour reduction after completion of the rhIL-6 treatment.
This latency is in accordance with previous findings in patients
with renal cell cancer who responded to other immunotherapy
(Wirth, 1993).
Toxicity, haematological and biochemical changes induced
by the subcutaneous rhIL-6 treatment were largely compar-
able with that previously reported in humans (Van Gameren
et al., 1994; Weber et al., 1993). In these previous studies
rhIL-6 was administered during a maximum of 7 consecutive
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study, revealed no tachyphylaxis for the main side-effects and
laboratory changes, as was previously documented in animal
studies with other cytokines (Takahashi et al., 1991). Since
toxicity was tolerable without requiring hospitalisation in the
majority of patients, we conclude that rhIL-6 can be safely
administered on an outpatient basis.
Anti-IL-6 antibodies during or after rhIL-6 treatment were
detectedin 15% ofthepatients. Halfofthesepatientshadstable
diseaseafterrhIL-6treatment,theotherhalfprogressivedisease.
Neutralising antibodies were detected in only one patient. It is
therefore concluded that our results were not affected by the
interference ofantibodies against the rhIL-6 used.
This study was initiated after observing a tumour response
of pulmonary metastases in a patient with renal cell
carcinoma after rhIL-6 treatment. The role of IL-6 in renal
cell carcinoma, however, is complex. Paraneoplastic symp-
toms, such as cachexia, fever, elevated erythrocyte sedimenta-
tion rate and anaemia, commonly observed in renal cell
cancer (Wirth, 1993), have been linked to the presence of
elevated plasma concentrations ofIL-6 in these patients (Blay
et al., 1992; Tsukamoto et al., 1992). As a source of IL-6 the
renal carcinoma itself could be appointed, since both normal
(Gogusev et al., 1993) and malignant renal cells (Tsukamoto
et al., 1992; Gogusev et al., 1993) have been shown to
produce and release IL-6. Moreover, in vitro data indicate
that IL-6 may act as an autocrine growth factor in these
tumours (Miki et al., 1989; Gruss et al., 1991; Koo et al.,
1992). On the other hand, IL-6 is not an independent
predictor of survival as would be predicted if it were a
clinically important autocrine growth factor (Stadler et al.,
1992). In our patient population neither endogenous baseline
IL-6 concentrations nor the exogenous IL-6 administration
could be related to tumour behaviour.
In two previous, preliminary reports a 5-day continuous
infusion of a 15-fold higher dosage of rhIL-6 (n= 12), or a 14
day course of s.c. rhIL-6 administration (n=1) in patients
with metastatic renal cell cancer resulted in no objective
responses (Ravoet et al., 1994; Weiss et al., 1994). We
observed a partial remission in only 2 out of 49 (4%)
patients. The patient characteristics of the responders in our
study were not discernible from those of the non-responders.
Therefore, at present rhIL-6 given as a daily s.c. injection for
6 weeks cannot be advocated as a treatment modality for
metastatic renal cell carcinoma. Our data further indicate,
however, that prolonged treatment with rhIL-6 can be
performed safely on an outpatient basis and is associated
with moderate, reversible toxicity. Finally, continuous rhIL-6
administration is accompanied by the development of non-
neutralising anti-IL-6 antibodies in only a minority of
patients.
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